FI85011C - Foerfarande foer framstaellning av farmakologiskt vaerdefulla fenetanolaminderivat. - Google Patents

Foerfarande foer framstaellning av farmakologiskt vaerdefulla fenetanolaminderivat. Download PDF

Info

Publication number
FI85011C
FI85011C FI841548A FI841548A FI85011C FI 85011 C FI85011 C FI 85011C FI 841548 A FI841548 A FI 841548A FI 841548 A FI841548 A FI 841548A FI 85011 C FI85011 C FI 85011C
Authority
FI
Finland
Prior art keywords
group
tai
general formula
methyl
ryhmä
Prior art date
Application number
FI841548A
Other languages
English (en)
Finnish (fi)
Swedish (sv)
Other versions
FI841548A7 (fi
FI85011B (fi
FI841548A0 (fi
Inventor
Ian Frederick Skidmore
Lawrence Henry Charles Lunts
Harry Finch
Alan Naylor
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27449465&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=FI85011(C) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from GB838310477A external-priority patent/GB8310477D0/en
Priority claimed from GB838317087A external-priority patent/GB8317087D0/en
Priority claimed from GB838329568A external-priority patent/GB8329568D0/en
Priority claimed from GB848401889A external-priority patent/GB8401889D0/en
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Publication of FI841548A0 publication Critical patent/FI841548A0/fi
Publication of FI841548A7 publication Critical patent/FI841548A7/fi
Publication of FI85011B publication Critical patent/FI85011B/fi
Application granted granted Critical
Publication of FI85011C publication Critical patent/FI85011C/fi

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C215/00—Compounds containing amino and hydroxy groups bound to the same carbon skeleton
    • C07C215/46—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C45/00—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds
    • C07C45/004—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by reaction with organometalhalides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/26—Psychostimulants, e.g. nicotine, cocaine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C229/00—Compounds containing amino and carboxyl groups bound to the same carbon skeleton
    • C07C229/38—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino groups bound to acyclic carbon atoms and carboxyl groups bound to carbon atoms of six-membered aromatic rings of the same carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C309/00—Sulfonic acids; Halides, esters, or anhydrides thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C33/00—Unsaturated compounds having hydroxy or O-metal groups bound to acyclic carbon atoms
    • C07C33/40—Halogenated unsaturated alcohols
    • C07C33/46—Halogenated unsaturated alcohols containing only six-membered aromatic rings as cyclic parts
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C43/00—Ethers; Compounds having groups, groups or groups
    • C07C43/02—Ethers
    • C07C43/03—Ethers having all ether-oxygen atoms bound to acyclic carbon atoms
    • C07C43/14—Unsaturated ethers
    • C07C43/17—Unsaturated ethers containing halogen
    • C07C43/174—Unsaturated ethers containing halogen containing six-membered aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C43/00—Ethers; Compounds having groups, groups or groups
    • C07C43/02—Ethers
    • C07C43/03—Ethers having all ether-oxygen atoms bound to acyclic carbon atoms
    • C07C43/14—Unsaturated ethers
    • C07C43/17—Unsaturated ethers containing halogen
    • C07C43/174—Unsaturated ethers containing halogen containing six-membered aromatic rings
    • C07C43/1742—Unsaturated ethers containing halogen containing six-membered aromatic rings with halogen atoms bound to the aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C43/00—Ethers; Compounds having groups, groups or groups
    • C07C43/02—Ethers
    • C07C43/03—Ethers having all ether-oxygen atoms bound to acyclic carbon atoms
    • C07C43/14—Unsaturated ethers
    • C07C43/178—Unsaturated ethers containing hydroxy or O-metal groups
    • C07C43/1782—Unsaturated ethers containing hydroxy or O-metal groups containing six-membered aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C43/00—Ethers; Compounds having groups, groups or groups
    • C07C43/02—Ethers
    • C07C43/20—Ethers having an ether-oxygen atom bound to a carbon atom of a six-membered aromatic ring
    • C07C43/225—Ethers having an ether-oxygen atom bound to a carbon atom of a six-membered aromatic ring containing halogen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C45/00—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds
    • C07C45/27—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by oxidation
    • C07C45/30—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by oxidation with halogen containing compounds, e.g. hypohalogenation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C47/00—Compounds having —CHO groups
    • C07C47/20—Unsaturated compounds having —CHO groups bound to acyclic carbon atoms
    • C07C47/277—Unsaturated compounds having —CHO groups bound to acyclic carbon atoms containing ether groups, groups, groups, or groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C49/00—Ketones; Ketenes; Dimeric ketenes; Ketonic chelates
    • C07C49/20—Unsaturated compounds containing keto groups bound to acyclic carbon atoms
    • C07C49/255—Unsaturated compounds containing keto groups bound to acyclic carbon atoms containing ether groups, groups, groups, or groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C59/40—Unsaturated compounds
    • C07C59/58—Unsaturated compounds containing ether groups, groups, groups, or groups
    • C07C59/64—Unsaturated compounds containing ether groups, groups, groups, or groups containing six-membered aromatic rings
    • C07C59/66—Unsaturated compounds containing ether groups, groups, groups, or groups containing six-membered aromatic rings the non-carboxylic part of the ether containing six-membered aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D303/00—Compounds containing three-membered rings having one oxygen atom as the only ring hetero atom
    • C07D303/02—Compounds containing oxirane rings
    • C07D303/38—Compounds containing oxirane rings with hydrocarbon radicals, substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D303/40—Compounds containing oxirane rings with hydrocarbon radicals, substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals by ester radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D309/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings
    • C07D309/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C07D309/08—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D309/10—Oxygen atoms
    • C07D309/12—Oxygen atoms only hydrogen atoms and one oxygen atom directly attached to ring carbon atoms, e.g. tetrahydropyranyl ethers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D317/00—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms
    • C07D317/08—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3
    • C07D317/44—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D317/46—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems condensed with one six-membered ring
    • C07D317/48—Methylenedioxybenzenes or hydrogenated methylenedioxybenzenes, unsubstituted on the hetero ring
    • C07D317/50—Methylenedioxybenzenes or hydrogenated methylenedioxybenzenes, unsubstituted on the hetero ring with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to atoms of the carbocyclic ring
    • C07D317/54—Radicals substituted by oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D319/00—Heterocyclic compounds containing six-membered rings having two oxygen atoms as the only ring hetero atoms
    • C07D319/04—1,3-Dioxanes; Hydrogenated 1,3-dioxanes
    • C07D319/06—1,3-Dioxanes; Hydrogenated 1,3-dioxanes not condensed with other rings
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Dermatology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Pulmonology (AREA)
  • Urology & Nephrology (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Compounds That Contain Two Or More Ring Oxygen Atoms (AREA)
  • Epoxy Compounds (AREA)
  • Pyrane Compounds (AREA)
FI841548A 1983-04-18 1984-04-18 Foerfarande foer framstaellning av farmakologiskt vaerdefulla fenetanolaminderivat. FI85011C (fi)

Applications Claiming Priority (8)

Application Number Priority Date Filing Date Title
GB8310477 1983-04-18
GB838310477A GB8310477D0 (en) 1983-04-18 1983-04-18 Chemical compounds
GB8317087 1983-06-23
GB838317087A GB8317087D0 (en) 1983-06-23 1983-06-23 Chemical compounds
GB8329568 1983-11-04
GB838329568A GB8329568D0 (en) 1983-11-04 1983-11-04 Chemical compounds
GB848401889A GB8401889D0 (en) 1984-01-25 1984-01-25 Chemical compounds
GB8401889 1984-01-25

Publications (4)

Publication Number Publication Date
FI841548A0 FI841548A0 (fi) 1984-04-18
FI841548A7 FI841548A7 (fi) 1984-10-19
FI85011B FI85011B (fi) 1991-11-15
FI85011C true FI85011C (fi) 1992-02-25

Family

ID=27449465

Family Applications (1)

Application Number Title Priority Date Filing Date
FI841548A FI85011C (fi) 1983-04-18 1984-04-18 Foerfarande foer framstaellning av farmakologiskt vaerdefulla fenetanolaminderivat.

Country Status (37)

Country Link
US (5) US4992474A (en, 2012)
JP (2) JPS63264443A (en, 2012)
KR (1) KR920004186B1 (en, 2012)
AR (3) AR244199A1 (en, 2012)
AT (1) AT390611B (en, 2012)
AU (1) AU573212B2 (en, 2012)
BE (1) BE899448A (en, 2012)
BG (1) BG61490B2 (en, 2012)
CA (2) CA1335999C (en, 2012)
CH (2) CH661497A5 (en, 2012)
CY (1) CY1482A (en, 2012)
CZ (1) CZ285602B6 (en, 2012)
DE (4) DE3448452C2 (en, 2012)
DK (2) DK167493B1 (en, 2012)
ES (2) ES531722A0 (en, 2012)
FI (1) FI85011C (en, 2012)
FR (1) FR2545482B1 (en, 2012)
GB (2) GB2140800B (en, 2012)
GR (1) GR79925B (en, 2012)
HK (1) HK36889A (en, 2012)
HU (1) HU200160B (en, 2012)
IE (1) IE57237B1 (en, 2012)
IL (1) IL71569A (en, 2012)
IT (1) IT1199112B (en, 2012)
KE (1) KE3864A (en, 2012)
LU (2) LU88265I2 (en, 2012)
MX (1) MX9203226A (en, 2012)
MY (1) MY102087A (en, 2012)
NL (2) NL188406C (en, 2012)
NO (2) NO159016C (en, 2012)
NZ (2) NZ221999A (en, 2012)
PH (1) PH21574A (en, 2012)
PT (1) PT78443B (en, 2012)
SE (1) SE462594B (en, 2012)
SG (1) SG12289G (en, 2012)
SK (1) SK278120B6 (en, 2012)
ZW (1) ZW6584A1 (en, 2012)

Families Citing this family (181)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZW6584A1 (en) * 1983-04-18 1985-04-17 Glaxo Group Ltd Phenethanolamine derivatives
ES8702880A1 (es) * 1984-04-17 1987-01-16 Glaxo Group Ltd Un procedimiento para la produccion de compuestos de fenetanolamina.
US4943591A (en) * 1984-10-17 1990-07-24 Glaxo Group Limited Dichloroaniline derivatives
GB8525321D0 (en) * 1985-10-15 1985-11-20 Glaxo Group Ltd Chemical compounds
EP0223410A3 (en) * 1985-10-16 1987-11-19 Glaxo Group Limited Ethanolamine derivatives
GB8525483D0 (en) * 1985-10-16 1985-11-20 Glaxo Group Ltd Chemical compounds
GB8525484D0 (en) * 1985-10-16 1985-11-20 Glaxo Group Ltd Chemical compounds
EP0220054A3 (en) * 1985-10-16 1987-12-02 Glaxo Group Limited Ethanolamine derivatives
JPS63290852A (ja) * 1987-02-10 1988-11-28 グラクソ、グループ、リミテッド 化合物
US4937268A (en) * 1987-03-12 1990-06-26 Glaxo Group Limited Chemical compounds
GB8718940D0 (en) * 1987-08-11 1987-09-16 Glaxo Group Ltd Chemical compounds
GB8718938D0 (en) * 1987-08-11 1987-09-16 Glaxo Group Ltd Chemical compounds
AU609209B2 (en) * 1987-11-13 1991-04-26 Glaxo Group Limited Phenethanolamine derivatives
ZA889405B (en) * 1987-12-18 1989-12-27 Glaxo Group Ltd Ethanolamine derivatives
NZ227365A (en) * 1987-12-18 1990-10-26 Glaxo Group Ltd Aromatic amino ethers and pharmaceutical compositions
GB2230775A (en) * 1989-04-24 1990-10-31 Glaxo Group Ltd Phenethanolamine compounds
GB8909273D0 (en) * 1989-04-24 1989-06-07 Glaxo Group Ltd Chemical compounds
CA2024789C (en) * 1989-09-07 2001-02-06 Malcolm Johnson Compounds for the treatment of inflammation and allergy
US5290815A (en) * 1989-09-07 1994-03-01 Glaxo Group Limited Treatment of inflammation and allergy
US5208226A (en) * 1989-09-08 1993-05-04 Glaxo Group Limited Medicaments
IL95590A (en) * 1989-09-08 1996-06-18 Glaxo Group Ltd Medicinal preparations containing Salmetrol and Pluticasone Propionate
US5270305A (en) * 1989-09-08 1993-12-14 Glaxo Group Limited Medicaments
CA2024872C (en) * 1989-09-08 2002-07-09 James Barry Douglas Palmer Medicaments
AU629989B2 (en) * 1989-10-10 1992-10-15 Glaxo Group Limited Phenethanolamine derivatives
HU213221B (en) 1990-03-02 1997-03-28 Glaxo Group Ltd Inhalation device and medicine packet for device
MY105368A (en) 1990-03-02 1994-09-30 Glaxo Group Ltd Inhalation device.
US6536427B2 (en) 1990-03-02 2003-03-25 Glaxo Group Limited Inhalation device
US5919827A (en) * 1990-07-11 1999-07-06 Sepracor Inc. Method for treating asthma using optically pure R(-) salmeterol
GB9026005D0 (en) * 1990-11-29 1991-01-16 Glaxo Group Ltd Drug material suitable for micronisation
WO1993016031A1 (en) * 1992-02-11 1993-08-19 Glaxo Group Limited Benzenedimethanol derivative suitable for micronisation
CN1056974C (zh) * 1992-02-11 2000-10-04 格拉克索公司 适宜于微粒化的药物材料的制备方法
AP323A (en) * 1992-05-08 1994-03-07 Glaxo Group Ltd Drug material suitable for micronisation.
GB9215274D0 (en) * 1992-07-17 1992-09-02 Scras Derivatives of(phenylethyl-beta-ol)amine
ES2065269B1 (es) * 1993-05-11 1995-10-01 S A L V A T Lab Sa 6-(4-(fenilbutoxi) hexilaminometil-4-hidroxi-a1,a3-bencenodimetanol. procedimiento para la obtencion del mismo y nuevos intermedios utilizados en su preparacion.
CA2177171C (en) * 1993-12-10 2006-01-17 Alfred Sallmann Novel substituted oxazolidines
GB9507768D0 (en) 1995-04-13 1995-05-31 Glaxo Group Ltd Method of apparatus
MX9707864A (es) 1995-04-14 1997-11-29 Glaxo Wellcome Inc Inhalador de dosis medida por salmeterol.
ES2179190T3 (es) 1995-04-14 2003-01-16 Smithkline Beecham Corp Inhalador dosificador para propianato de fluticasona.
SK139197A3 (en) 1995-04-14 1998-04-08 Glaxo Wellcome Inc Metered dose inhaler for beclomethasone dipropionate
RO119118B1 (ro) 1995-04-14 2004-04-30 Glaxo Wellcome Inc. Inhalator cu doză fixă pentru albuterol
US6632955B1 (en) 1996-12-02 2003-10-14 Chisso Corporation Optically active nitro alcohol derivatives, optically active amino alcohol derivatives, and process for preparing the same
US6254882B1 (en) 1997-09-16 2001-07-03 Sepracor Inc. Methods and compositions for treating pulmonary disorders using optically pure (S)—salmeterol
JP2002516828A (ja) * 1998-06-01 2002-06-11 アンソニー・ジェイ・バービスカー 局所経皮治療
ES2142771B1 (es) * 1998-09-28 2001-01-01 Vita Invest Sa Nuevos derivados de la 6-(4-fenil-butoxi) hexilamina y procedimiento para la obtencion de salmeterol.
DE60001492T2 (de) 1999-04-14 2003-12-18 Glaxo Group Ltd., Greenford Pharmazeutische aerosolformulierung
ES2260043T3 (es) * 1999-08-21 2006-11-01 Altana Pharma Ag Combinacion sinergica de roflumilast y salmeterol.
GB0009613D0 (en) * 2000-04-18 2000-06-07 Glaxo Group Ltd Pharmaceutical compositions
GB0009609D0 (en) * 2000-04-18 2000-06-07 Glaxo Group Ltd Therapeutic compositions
GB0014546D0 (en) * 2000-06-14 2000-08-09 Glaxo Group Ltd A novel process
GB0015043D0 (en) 2000-06-21 2000-08-09 Glaxo Group Ltd Medicament dispenser
US6750210B2 (en) 2000-08-05 2004-06-15 Smithkline Beecham Corporation Formulation containing novel anti-inflammatory androstane derivative
GB0019172D0 (en) 2000-08-05 2000-09-27 Glaxo Group Ltd Novel compounds
US6787532B2 (en) 2000-08-05 2004-09-07 Smithkline Beecham Corporation Formulation containing anti-inflammatory androstane derivatives
US6777400B2 (en) * 2000-08-05 2004-08-17 Smithkline Beecham Corporation Anti-inflammatory androstane derivative compositions
ATE380194T1 (de) 2000-08-05 2007-12-15 Glaxo Group Ltd 6.alpha.,9.alpha.-difluoro-17.alpha.-(2-
US6858596B2 (en) * 2000-08-05 2005-02-22 Smithkline Beecham Corporation Formulation containing anti-inflammatory androstane derivative
US6858593B2 (en) 2000-08-05 2005-02-22 Smithkline Beecham Corporation Anti-inflammatory androstane derivative compositions
US6759398B2 (en) * 2000-08-05 2004-07-06 Smithkline Beecham Corporation Anti-inflammatory androstane derivative
US6777399B2 (en) 2000-08-05 2004-08-17 Smithkline Beecham Corporation Anti-inflammatory androstane derivative compositions
US20030207057A1 (en) 2000-09-18 2003-11-06 Britto Ignatius Loy Metered dose inhaler can coated two or more times with fluorocarbon polymers
GB0103630D0 (en) 2001-02-14 2001-03-28 Glaxo Group Ltd Chemical compounds
JP2004526720A (ja) 2001-03-08 2004-09-02 グラクソ　グループ　リミテッド βアドレナリン受容体のアゴニスト
IL157580A0 (en) * 2001-03-20 2004-03-28 Glaxo Group Ltd Inhalation drug combination
ES2296923T3 (es) * 2001-03-22 2008-05-01 Glaxo Group Limited Derivados formanilidas como agonistas del adrenorreceptor beta2.
UA77656C2 (en) 2001-04-07 2007-01-15 Glaxo Group Ltd S-fluoromethyl ester of 6-alpha, 9-alpha-difluoro-17-alpha-[(2-furanylcarbonyl)oxy]-11-beta-hydroxy-16- alpha-methyl-3-oxoandrosta-1,4-dien-17-beta-carbothioacid as anti-inflammatory agent
US6667344B2 (en) 2001-04-17 2003-12-23 Dey, L.P. Bronchodilating compositions and methods
US20030055026A1 (en) * 2001-04-17 2003-03-20 Dey L.P. Formoterol/steroid bronchodilating compositions and methods of use thereof
DE60229372D1 (de) * 2001-04-30 2008-11-27 Glaxo Group Ltd Antiphlogistische 7.beta.-carbothioate esterderivate von androstan mit einer 17.alpha.-zyklischen estergruppe
US7238680B2 (en) * 2001-06-01 2007-07-03 Rosen Steven E Topical compositions for veterinary uses
ES2316599T3 (es) 2001-09-14 2009-04-16 Glaxo Group Limited Derivados de fenetanolamina para el tratamiento de enfermedades respiratorias.
US6680345B2 (en) 2001-09-14 2004-01-20 Boehringer Ingelheim Pharma Kg Salicylic acid salts of salmeterol
JP4199114B2 (ja) * 2001-09-14 2008-12-17 ベーリンガー インゲルハイム ファルマ ゲゼルシャフト ミット ベシュレンクテル ハフツング ウント コンパニー コマンディトゲゼルシャフト サリチル酸塩、その製法及び医薬組成物としての使用
US6653323B2 (en) 2001-11-13 2003-11-25 Theravance, Inc. Aryl aniline β2 adrenergic receptor agonists
US20030229058A1 (en) * 2001-11-13 2003-12-11 Moran Edmund J. Aryl aniline beta2 adrenergic receptor agonists
TWI249515B (en) 2001-11-13 2006-02-21 Theravance Inc Aryl aniline beta2 adrenergic receptor agonists
US20050175545A1 (en) * 2002-02-04 2005-08-11 Keith Biggadike Formulation for inhalation comprising a glucocorticoid and a beta 2-adrenoreceptor agonist
GB0202635D0 (en) * 2002-02-05 2002-03-20 Glaxo Wellcome Mfg Pte Ltd Formulation containing novel anti-inflammatory androstane derivative
CA2477714C (en) * 2002-03-04 2011-01-25 Boehringer Ingelheim Pharma Gmbh & Co. Kg New cinnamic acid salts, processes for the preparation thereof and use thereof as medicament
US6756508B2 (en) 2002-03-04 2004-06-29 Boehringer Ingelheim Pharma Gmbh & Co. Kg Cinnamic acid salts, processes for their preparation, and their use as medicaments
US6835857B2 (en) 2002-03-05 2004-12-28 Boehringer Ingelheim Pharma Gmbh & Co. Kg Process for the manufacture of 4-(6-bromohexyloxy)-butylbenzene
DE10209583B4 (de) * 2002-03-05 2006-01-19 Boehringer Ingelheim Pharma Gmbh & Co. Kg Verfahren zur Herstellung von 4-(6-Bromhexyloxy)-butylbenzol
EP1503754B1 (en) * 2002-04-19 2005-11-23 Yissum Research Development Company, of The Hebrew University of Jerusalem Beta-agonist compounds comprising nitric oxide donor groups and reactive oxygen species scavenger groups and their use in the treatment of respiratory disorders
DE60318193T2 (de) * 2002-04-25 2008-12-04 Glaxo Group Ltd., Greenford Phenethanolaminderivate
JP2005527618A (ja) 2002-05-28 2005-09-15 セラヴァンス インコーポレーテッド アルコキシアリールβ２アドレナリン作動性レセプターアゴニスト
GB2389530B (en) 2002-06-14 2007-01-10 Cipla Ltd Pharmaceutical compositions
GB0217225D0 (en) * 2002-07-25 2002-09-04 Glaxo Group Ltd Medicinal compounds
US20040023935A1 (en) * 2002-08-02 2004-02-05 Dey, L.P. Inhalation compositions, methods of use thereof, and process for preparation of same
DE10249576B3 (de) * 2002-10-24 2004-04-08 Boehringer Ingelheim Pharma Gmbh & Co. Kg Verfahren zur Herstellung von (R)-Salbutamol
CA2503588A1 (en) 2002-10-28 2004-05-06 Glaxo Group Limited Phenethanolamine derivative for the treatment of respiratory diseases
GB0225030D0 (en) * 2002-10-28 2002-12-04 Glaxo Group Ltd Medicinal compounds
GB0225535D0 (en) * 2002-11-01 2002-12-11 Glaxo Group Ltd Medicinal compounds
US20040109826A1 (en) * 2002-12-06 2004-06-10 Dey, L.P. Stabilized albuterol compositions and method of preparation thereof
US20060076010A1 (en) * 2002-12-18 2006-04-13 King Michael L Drug delivery system with vented mouthpiece
PE20040950A1 (es) * 2003-02-14 2005-01-01 Theravance Inc DERIVADOS DE BIFENILO COMO AGONISTAS DE LOS RECEPTORES ADRENERGICOS ß2 Y COMO ANTAGONISTAS DE LOS RECEPTORES MUSCARINICOS
GB0303396D0 (en) 2003-02-14 2003-03-19 Glaxo Group Ltd Medicinal compounds
JP4767842B2 (ja) * 2003-04-01 2011-09-07 セラヴァンス， インコーポレーテッド β２アドレナリン作用性レセプターアゴニスト活性およびムスカリン性レセプターアンタゴニスト活性を有するジアリールメチル化合物および関連化合物
US20040226556A1 (en) 2003-05-13 2004-11-18 Deem Mark E. Apparatus for treating asthma using neurotoxin
ES2329133T3 (es) * 2003-05-28 2009-11-23 Theravance, Inc. Compuestos azabicicloalcanicos como antagonistas de receptores de muscarinicos.
TWI359675B (en) 2003-07-10 2012-03-11 Dey L P Bronchodilating β-agonist compositions
US20090285900A1 (en) * 2003-07-31 2009-11-19 Robinson Cynthia B Combination of dehydroepiandrosterone or dehydroepiandrosterone-sulfate with a beta-agonist bronchodilator for treatment of asthma or chronic obstructive pulmonary disease
US20050113318A1 (en) * 2003-07-31 2005-05-26 Robinson Cynthia B. Combination of dehydroepiandrosterone or dehydroepiandrosterone-sulfate with a beta-agonist bronchodilator for treatment of asthma or chronic obstructive pulmonary disease
US20050026884A1 (en) * 2003-07-31 2005-02-03 Robinson Cynthia B. Combination of dehydroepiandrosterone or dehydroepiandrosterone-sulfate with a beta-agonist bronchodilator for treatment of asthma or chronic obstructive pulmonary disease
US8198354B2 (en) 2003-08-11 2012-06-12 Glaxo Group Limited Pharmaceutical metered dose inhaler and methods relating thereto
GB0319826D0 (en) * 2003-08-22 2003-09-24 Glaxo Group Ltd Process
WO2005021515A2 (en) * 2003-08-29 2005-03-10 Ranbaxy Laboratories Limited Inhibitors of phosphodiesterase type-iv
TW200526547A (en) * 2003-09-22 2005-08-16 Theravance Inc Amino-substituted ethylamino β2 adrenergic receptor agonists
GB0324654D0 (en) * 2003-10-22 2003-11-26 Glaxo Group Ltd Medicinal compounds
GB0324886D0 (en) * 2003-10-24 2003-11-26 Glaxo Group Ltd Medicinal compounds
WO2005051931A2 (en) * 2003-11-26 2005-06-09 Ranbaxy Laboratories Limited Phosphodiesterase inhibitors
SE0303570L (sv) * 2003-12-03 2005-06-04 Microdrug Ag Fukt-känslig medicinsk produkt
AU2004294889B2 (en) * 2003-12-03 2010-08-26 Boehringer Ingelheim International Gmbh Medical product containing tiotropium
SE0303270L (sv) * 2003-12-03 2005-06-04 Microdrug Ag Metod för administration av tiotropium
GB0329182D0 (en) * 2003-12-17 2004-01-21 Glaxo Group Ltd Chemical compounds
TW200531692A (en) * 2004-01-12 2005-10-01 Theravance Inc Aryl aniline derivatives as β2 adrenergic receptor agonists
JP2007528889A (ja) * 2004-03-12 2007-10-18 シプラ・リミテッド 吸入製剤
CN1984876A (zh) * 2004-06-03 2007-06-20 施万制药 二胺类β2肾上腺素能受体激动剂
US7317023B2 (en) * 2004-07-21 2008-01-08 Theravance, Inc. Diaryl ether β2 adrenergic receptor agonists
JP2008512470A (ja) * 2004-09-10 2008-04-24 セラヴァンス， インコーポレーテッド アミジン置換アリールアニリン化合物
CA2581999C (en) 2004-10-12 2013-04-23 Generics (Uk) Limited Preparation of suspension aerosol formulations
EP1949891A1 (en) 2004-10-12 2008-07-30 Generics (UK) Limited Process for the preparation of suspension aerosol formulations, wherein the particles are formed by precipitation inside an aerosol canister
GB0507165D0 (en) * 2005-04-08 2005-05-18 Glaxo Group Ltd Novel crystalline pharmaceutical product
ES2265276B1 (es) 2005-05-20 2008-02-01 Laboratorios Almirall S.A. Derivados de 4-(2-amino-1-hidroxietil)fenol como agonistas del receptor beta2 adrenergico.
DE102005033732B4 (de) * 2005-05-27 2014-02-13 Grünenthal GmbH Trennung stereoisomerer N,N-Dialkylamino-2-alkyl-3-hydroxy-3-phenyl-alkane
WO2007008427A2 (en) * 2005-07-08 2007-01-18 Xemplar Pharmaceuticals, Llc Aerosol compositions and methods
US8429052B2 (en) * 2005-07-19 2013-04-23 Lincoln National Life Insurance Company Method and system for providing employer-sponsored retirement plan
TWI274641B (en) * 2005-08-30 2007-03-01 Rexon Ind Corp Ltd Cutting machine
EP1934219A1 (en) 2005-09-16 2008-06-25 Ranbaxy Laboratories Limited Substituted pyrazolo [3,4-b] pyridines as phosphodiesterase inhibitors
WO2007045857A1 (en) 2005-10-17 2007-04-26 Generics (Uk) Limited Novel process
WO2007045979A1 (en) 2005-10-19 2007-04-26 Ranbaxy Laboratories Limited Pharmaceutical compositions of muscarinic receptor antagonists
US20090054382A1 (en) * 2005-10-19 2009-02-26 Abhijit Ray Compositions of phosphodiesterase type iv inhibitors
WO2007079466A2 (en) * 2006-01-04 2007-07-12 Nano Mist International, Llc Air driven delivery system for sprayable media
GB0602778D0 (en) * 2006-02-10 2006-03-22 Glaxo Group Ltd Novel compound
WO2007103970A2 (en) * 2006-03-07 2007-09-13 Endacea, Inc. Compositions and methods for treating respiratory disorders
ES2296516B1 (es) * 2006-04-27 2009-04-01 Laboratorios Almirall S.A. Derivados de 4-(2-amino-1-hidroxietil)fenol como agonistas del receptor beta2 adrenergico.
US20070286814A1 (en) * 2006-06-12 2007-12-13 Medispray Laboratories Pvt. Ltd. Stable aerosol pharmaceutical formulations
GB0615108D0 (en) * 2006-07-28 2006-09-06 Glaxo Group Ltd Novel formulations
CL2007002427A1 (es) * 2006-08-22 2008-03-14 Ranbaxy Lab Ltd Compuestos derivados heterociclicos, inhibidores de metaloproteinasa de matriz; proceso de preparacion; composicion farmaceutica, util para el tratamiento o profilaxis de enfermedades inflamatorias o desordenes autoinmunes.
EA200900472A1 (ru) * 2006-09-22 2009-10-30 Ранбакси Лабораторис Лимитед Ингибиторы фосфодиэстеразы iv типа
EP2066661A2 (en) * 2006-09-22 2009-06-10 Ranbaxy Laboratories Limited Phosphodiesterase inhibitors
ES2302447B1 (es) * 2006-10-20 2009-06-12 Laboratorios Almirall S.A. Derivados de 4-(2-amino-1-hidroxietil)fenol como agonistas del receptor beta2 adrenergico.
ES2306595B1 (es) 2007-02-09 2009-09-11 Laboratorios Almirall S.A. Sal de napadisilato de 5-(2-((6-(2,2-difluoro-2-feniletoxi)hexil)amino)-1-hidroxietil)-8-hidroxiquinolin-2(1h)-ona como agonista del receptor adrenergico beta2.
EP1958947A1 (en) 2007-02-15 2008-08-20 Ranbaxy Laboratories Limited Inhibitors of phosphodiesterase type 4
WO2008111010A1 (en) * 2007-03-14 2008-09-18 Ranbaxy Laboratories Limited Pyrazolo (3, 4-b) pyridine derivatives as phosphodiesterase inhibitors
EP2124943A1 (en) * 2007-03-14 2009-12-02 Ranbaxy Laboratories Limited Pyrazolo [3, 4-b]pyridine derivatives as phosphodiesterase inhibitors
US20080319086A1 (en) * 2007-06-20 2008-12-25 Protia, Llc Deuterium-enriched salmeterol
US20090048155A1 (en) 2007-08-15 2009-02-19 Endacea, Inc. Methods for preventing and treating tissue injury and sepsis associated with Yersinia pestis infection
ES2320961B1 (es) 2007-11-28 2010-03-17 Laboratorios Almirall, S.A. Derivados de 4-(2-amino-1-hidroxietil)fenol como agonistas del receptor adrenergico beta2.
EP2222676A4 (en) 2007-12-21 2011-10-26 Endacea Inc A1-adenosine receptor antagonistic
US8483831B1 (en) 2008-02-15 2013-07-09 Holaira, Inc. System and method for bronchial dilation
WO2009134524A2 (en) 2008-02-26 2009-11-05 Elevation Pharmaceuticals, Inc. Method and system for the treatment of chronic obstructive pulmonary disease with nebulized anticholinergic administrations
US20100055045A1 (en) 2008-02-26 2010-03-04 William Gerhart Method and system for the treatment of chronic obstructive pulmonary disease with nebulized anticholinergic administrations
EP2111861A1 (en) 2008-04-21 2009-10-28 Ranbaxy Laboratories Limited Compositions of phosphodiesterase type IV inhibitors
EP2662046B1 (en) 2008-05-09 2023-03-15 Nuvaira, Inc. Systems and assemblies for treating a bronchial tree
EP2127641A1 (en) 2008-05-26 2009-12-02 Inke, S.A. Micronisable form of salmeterol xinafoate
UY32297A (es) 2008-12-22 2010-05-31 Almirall Sa Sal mesilato de 5-(2-{[6-(2,2-difluoro-2-fenilitoxi) hexil]amino}-1-hidroxietil)-8-hidroxiquinolin-2( 1h)-ona como agonista del receptor b(beta)2 acrenérgico
EP2221055A1 (en) * 2009-02-18 2010-08-25 Almirall, S.A. 5-(2-{[6-(2,2-difluoro-2-phenylethoxy)hexyl]amino}-1-hydroxyethyl)-8-hydroxyquinolin-2(1H)-one for the treatment of lung function
EP2228368A1 (en) 2009-03-12 2010-09-15 Almirall, S.A. Process for manufacturing 5-(2-{[6-(2,2-difluoro-2-phenylethoxy) hexyl]amino}-1-hydroxyethyl)-8-hydroxyquinolin-2(1H)-one
US8815258B2 (en) 2009-05-29 2014-08-26 Pearl Therapeutics, Inc. Compositions, methods and systems for respiratory delivery of two or more active agents
JP5873013B2 (ja) 2009-05-29 2016-03-01 パール セラピューティクス，インコーポレイテッド ２つ以上の活性剤を呼吸器送達するための組成物、方法および系
KR101722290B1 (ko) 2009-10-27 2017-03-31 호라이라 인코포레이티드 냉각 가능한 에너지 에미팅 어셈블리를 갖는 전달 장치
US8911439B2 (en) 2009-11-11 2014-12-16 Holaira, Inc. Non-invasive and minimally invasive denervation methods and systems for performing the same
JP6000851B2 (ja) 2009-11-11 2016-10-05 ホライラ， インコーポレイテッド 組織治療および狭窄制御のためのシステム、装置、および方法
TR201000685A2 (tr) 2010-01-29 2011-08-22 Bi̇lgi̇ç Mahmut Salmeterol ve flutikazon içeren farmasötik preparatlar.
US8367829B2 (en) 2010-05-10 2013-02-05 Gilead Sciences, Inc. Bi-functional pyrazolopyridine compounds
WO2011143105A1 (en) 2010-05-10 2011-11-17 Gilead Sciences, Inc. Bifunctional quinoline derivatives
CN103119030A (zh) 2010-07-30 2013-05-22 兰贝克赛实验室有限公司 基质金属蛋白酶抑制剂
WO2012032546A2 (en) 2010-09-08 2012-03-15 Cadila Healthcare Limited Process for the preparation of salmeterol and its intermediates
BR112013006932A2 (pt) 2010-09-24 2016-07-12 Ranbaxy Lab Ltd composto composição farmacêutica e processo para preparar um composto
EP2578570A1 (en) 2011-10-07 2013-04-10 Almirall, S.A. Novel process for preparing 5-(2-{[6-(2,2-difluoro-2-phenylethoxy)hexyl]amino}-1(r)-hydroxyethyl)-8-hydroxyquinolin-2(1h)-one via novel intermediates of synthesis.
EP2641900A1 (en) 2012-03-20 2013-09-25 Almirall, S.A. Novel polymorphic Crystal forms of 5-(2-{[6-(2,2-difluoro-2-phenylethoxy) hexyl]amino}-1-(R)-hydroxyethyl)-8-hydroxyquinolin-2(1h)-one, heminapadisylate as agonist of the ß2 adrenergic receptor.
CN103864629A (zh) * 2012-12-13 2014-06-18 天津金耀集团有限公司 昔萘酸沙美特罗的精制方法
US9398933B2 (en) 2012-12-27 2016-07-26 Holaira, Inc. Methods for improving drug efficacy including a combination of drug administration and nerve modulation
MX361286B (es) 2013-03-15 2018-12-03 Pearl Therapeutics Inc Métodos y sistemas para el acondicionamiento de materiales cristalinos de partículas.
EP2815739B1 (en) 2013-06-17 2019-08-28 Arven Ilac Sanayi Ve Ticaret A.S. Inhalation composition filling method
CN104744271B (zh) * 2013-12-26 2016-08-31 成都伊诺达博医药科技有限公司 一种合成维兰特罗的新工艺
US9447067B2 (en) 2014-10-03 2016-09-20 Amphastar Pahmaceuticals, Inc. Method of preparing intermediate of salmeterol
WO2016142582A1 (en) 2015-03-11 2016-09-15 Fermion Oy Process for the preparation of crystalline salmeterol and its xinafoate salt
CN114685291B (zh) * 2020-12-30 2025-06-17 天津药业研究院股份有限公司 沙美特罗的制备方法和应用
RS65598B1 (sr) 2021-07-09 2024-06-28 Astrazeneca Pharmaceuticals Lp Sastavi, postupci i sistemi za isporuku aerosolnog leka
JP2024545816A (ja) 2021-12-20 2024-12-12 アストラゼネカ・アクチエボラーグ エアロゾル薬物送達のための組成物、方法及びシステム
IL318013A (en) * 2022-06-26 2025-02-01 Alexander Shulgin Res Institute Inc N-substituted phenylalkylamines and their use as therapeutic agents

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR1451357A (fr) * 1965-07-01 1966-01-07 Soc Ind Fab Antibiotiques Sifa Nouveaux alcools dérivés de l'éthano-9, 10 dihydro-9, 10 anthracene et procédé de préparation
GB1200886A (en) * 1966-09-23 1970-08-05 Allen & Hanburys Ltd Phenylaminoethanol derivatives
GB1321701A (en) * 1969-10-01 1973-06-27 Continental Pharma Amino-alcohols their salts and process for prepairing the same
US4137328A (en) * 1970-07-18 1979-01-30 Pfizer Inc. Phenyl-alkanolamine, alkylamine and α-aminoalkyl ketone derivatives as heart stimulants
AT310146B (de) * 1971-04-26 1973-09-25 Boehringer Sohn Ingelheim Verfahren zur Herstellung von neuen N,N'-Bis-(β-hydroxyaryläthyl)-diaminoalkanen und deren Säureadditionssalzen
US3879442A (en) * 1972-07-27 1975-04-22 Warner Lambert Co 5-hydroxy-{60 (substituted aminomethyl)-mu-xylene-{60 ,{60 -diols
GB1511159A (en) * 1975-07-10 1978-05-17 Leo A Amines preparation
GB1529972A (en) * 1975-07-29 1978-10-25 Allen & Hanburys Ltd Basic alcohols
US4160036A (en) * 1975-07-29 1979-07-03 Allen & Hanburys Limited 4-Hydroxy-1,3-benzenedimethanol derivatives
US4154761A (en) * 1976-02-09 1979-05-15 Allen & Hanburys Limited Pharmacologically active compounds
JPS52113934A (en) * 1976-03-19 1977-09-24 Eisai Co Ltd Phenethylamine derivatives and bronchodilator containing the same
US4233302A (en) * 1977-12-23 1980-11-11 Glaxo Group Limited Amine derivatives and pharmaceutical compositions containing them
DE2833140A1 (de) * 1978-07-28 1980-02-07 Boehringer Sohn Ingelheim Neue n-substituierte heterocyclen
US4160367A (en) * 1978-09-11 1979-07-10 General Motors Corporation Dual container additive dispenser for appliance
ATE1899T1 (de) * 1979-06-16 1982-12-15 Beecham Group Plc Sekundaere amine, ihre herstellung und verwendung in pharmazeutischen zusammensetzungen.
FR2460919A1 (fr) * 1979-07-11 1981-01-30 Prod Synthese Ste Indle Amino-ethers oxydes, leur procede de preparation et leur application en therapeutique
US4288456A (en) * 1980-09-19 1981-09-08 E. R. Squibb & Sons, Inc. Compositions containing 1-aryl-5-(2-propenylamino)-1-penten-3-ones and method for treating inflammatory conditions
US4379166A (en) * 1981-08-03 1983-04-05 Schering Corporation Arylmethoxy-, arylmethylthio-, heteroarylmethoxy-, and heteroarylmethylthio-alkylaminoalcohols
EP0103830A3 (de) * 1982-09-22 1985-07-31 Bayer Ag Wachstumsfördernde Phenylethylamin-Derivate
ZW6584A1 (en) * 1983-04-18 1985-04-17 Glaxo Group Ltd Phenethanolamine derivatives
US4985459A (en) * 1984-02-08 1991-01-15 Richardson-Vicks, Inc. Analgesic and anti-inflammatory compositions comprising diphenhydramine and methods of using same
ES8702880A1 (es) * 1984-04-17 1987-01-16 Glaxo Group Ltd Un procedimiento para la produccion de compuestos de fenetanolamina.

Also Published As

Publication number Publication date
DK167493B1 (da) 1993-11-08
PT78443B (en) 1986-08-28
IL71569A (en) 1987-10-30
FR2545482A1 (fr) 1984-11-09
BE899448A (fr) 1984-10-18
DE3414752A1 (de) 1984-10-18
PH21574A (en) 1987-12-11
ES8609209A1 (es) 1986-07-16
US5243076A (en) 1993-09-07
LU88265I2 (en, 2012) 1994-02-03
NO841568L (no) 1984-10-19
CZ285602B6 (cs) 1999-09-15
KR840009063A (ko) 1984-12-24
AU2706484A (en) 1984-10-25
NO1994017I1 (no) 1994-09-22
US5225445A (en) 1993-07-06
GB2140800B (en) 1987-09-23
GB2176476A (en) 1986-12-31
KE3864A (en) 1989-05-19
SE8402188L (sv) 1984-10-19
JPH0687800A (ja) 1994-03-29
DE19575029I2 (de) 2002-11-07
US5126375A (en) 1992-06-30
ES8505641A1 (es) 1985-06-01
JPH0729997B2 (ja) 1995-04-05
SK402891A3 (en) 1995-07-11
NL930066I2 (nl) 1993-10-01
AR245687A1 (es) 1994-02-28
SG12289G (en) 1989-07-07
CZ402891A3 (en) 1993-05-12
GB8612357D0 (en) 1986-06-25
IE840965L (en) 1984-10-18
JPH0569817B2 (en, 2012) 1993-10-01
CH667084A5 (fr) 1988-09-15
FI841548A7 (fi) 1984-10-19
GB8410124D0 (en) 1984-05-31
DE3448452C2 (de) 1994-01-05
IT1199112B (it) 1988-12-30
US5091422A (en) 1992-02-25
NO159016C (no) 1988-11-23
NO159016B (no) 1988-08-15
NL8401258A (nl) 1984-11-16
AR247721A1 (es) 1995-03-31
SE462594B (sv) 1990-07-23
NL188406B (nl) 1992-01-16
FI85011B (fi) 1991-11-15
DK201784A (da) 1984-10-19
NL930066I1 (nl) 1993-09-01
GR79925B (en, 2012) 1984-10-31
ATA129184A (de) 1989-11-15
DK201784D0 (da) 1984-04-18
LU85329A1 (fr) 1985-06-04
IT8448064A0 (it) 1984-04-18
ES539625A0 (es) 1986-07-16
HU200160B (en) 1990-04-28
CA1335999C (en) 1995-06-20
ES531722A0 (es) 1985-06-01
NZ207885A (en) 1988-11-29
JPS63264443A (ja) 1988-11-01
MX9203226A (es) 1992-07-01
PT78443A (pt) 1984-05-01
MY102087A (en) 1992-03-31
GB2140800A (en) 1984-12-05
NZ221999A (en) 1988-11-29
DK158092A (da) 1992-12-30
ZW6584A1 (en) 1985-04-17
DE3448338C2 (en, 2012) 1993-05-19
CA1336004C (en) 1995-06-20
SE8402188D0 (sv) 1984-04-18
NL188406C (nl) 1992-06-16
GB2176476B (en) 1987-12-31
IL71569A0 (en) 1984-07-31
CY1482A (en) 1989-12-08
BG61490B2 (bg) 1997-09-30
SK278120B6 (en) 1996-02-07
DK175083B1 (da) 2004-05-24
DK158092D0 (da) 1992-12-30
US4992474A (en) 1991-02-12
DE3414752C2 (en, 2012) 1993-03-25
AR244199A1 (es) 1993-10-29
FI841548A0 (fi) 1984-04-18
HK36889A (en) 1989-05-12
AT390611B (de) 1990-06-11
IE57237B1 (en) 1992-06-17
FR2545482B1 (fr) 1988-06-17
CH661497A5 (fr) 1987-07-31
AU573212B2 (en) 1988-06-02
KR920004186B1 (ko) 1992-05-30

Similar Documents

Publication Publication Date Title
FI85011C (fi) Foerfarande foer framstaellning av farmakologiskt vaerdefulla fenetanolaminderivat.
EP0162576B1 (en) Ethanolamine compounds
JPH07103056B2 (ja) 神経細胞変性修復又は保護剤
JP2002518374A (ja) 治療用ビアリール誘導体
NO852809L (no) Fremgangsmaate for fremstilling av terapeutisk aktive aminofenolderivater.
EP0445749B1 (en) N-Monosubstituted cyclopentenylamines, a process for their preparation and their use as medicaments
EP0703913B1 (en) Imidazoles as lipoxygenase inhibitors
US5066678A (en) Phenethandamine derivatives and pharmaceutical use thereof
HU211554A9 (en) Circulation-active dibenzo/1,5/dioxocin-5-ones
JPH03858B2 (en, 2012)
AU635424B2 (en) Dichloroaniline compound
US5624948A (en) 1-(2-benzimidazolyl)-1,5-diazacyclooctane compounds
EP0288202A2 (en) Fluoro-sulfones
NO861370L (no) Fremgangsm te for fremstilling av terapeutisk aktivranilin-derivater.
FR2783247A1 (fr) Derives de 2-aminoethyl-quinoleine, leur preparation et leur application en therapeutique
PL141862B1 (en) Method of obtaining novel derivatives of phenyloethanoloamine
PL141883B1 (en) Method of obtaining novel derivatives of phenylethanolamine

Legal Events

Date Code Title Description
ND Supplementary protection certificate (spc) granted
SPCG Supplementary protection certificate granted

Spc suppl protection certif: L13

Extension date: 20051025

MA Patent expired

Owner name: GLAXO GROUP LIMITED